The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ravuconazole     4-[2-[(2R,3R)-3-(2,4- difluorophenyl)-3...

Synonyms: CHEMBL294029, SureCN939026, AG-K-23435, BMS-207147, AC1LAG1H, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ravuconazole


High impact information on Ravuconazole


Chemical compound and disease context of Ravuconazole


Biological context of Ravuconazole


Anatomical context of Ravuconazole


Associations of Ravuconazole with other chemical compounds


Gene context of Ravuconazole

  • The activity of BMS-207147 was minimally affected by overexpression of the gene encoding the efflux pump MDR1, but MIC increases were observed with changes in ERG11 and with overexpression of the CDR transporter gene [21].
  • These findings are consistent with the potential for ravuconazole to both inhibit and induce CYP3A isozymes [22].

Analytical, diagnostic and therapeutic context of Ravuconazole


  1. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Hata, K., Kimura, J., Miki, H., Toyosawa, T., Nakamura, T., Katsu, K. Antimicrob. Agents Chemother. (1996) [Pubmed]
  2. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Hata, K., Kimura, J., Miki, H., Toyosawa, T., Moriyama, M., Katsu, K. Antimicrob. Agents Chemother. (1996) [Pubmed]
  3. Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Clemons, K.V., Stevens, D.A. Antimicrob. Agents Chemother. (2001) [Pubmed]
  4. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. Meletiadis, J., Petraitis, V., Petraitiene, R., Lin, P., Stergiopoulou, T., Kelaher, A.M., Sein, T., Schaufele, R.L., Bacher, J., Walsh, T.J. J. Infect. Dis. (2006) [Pubmed]
  5. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Garcia-Effron, G., Monzon, A., Rodriguez-Tudela, J.L. Antimicrob. Agents Chemother. (2005) [Pubmed]
  6. In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Garcia-Effron, G., Rodriguez-Tudela, J.L. Antimicrob. Agents Chemother. (2004) [Pubmed]
  7. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Petraitiene, R., Petraitis, V., Lyman, C.A., Groll, A.H., Mickiene, D., Peter, J., Bacher, J., Roussillon, K., Hemmings, M., Armstrong, D., Avila, N.A., Walsh, T.J. Antimicrob. Agents Chemother. (2004) [Pubmed]
  8. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. Petraitis, V., Petraitiene, R., Sarafandi, A.A., Kelaher, A.M., Lyman, C.A., Casler, H.E., Sein, T., Groll, A.H., Bacher, J., Avila, N.A., Walsh, T.J. J. Infect. Dis. (2003) [Pubmed]
  9. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Roberts, J., Schock, K., Marino, S., Andriole, V.T. Antimicrob. Agents Chemother. (2000) [Pubmed]
  10. Impact of real-time fungal susceptibility on clinical practices. Magiorakos, A.P., Hadley, S. Curr. Opin. Infect. Dis. (2004) [Pubmed]
  11. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Andes, D., Marchillo, K., Stamstad, T., Conklin, R. Antimicrob. Agents Chemother. (2003) [Pubmed]
  12. Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. Groll, A.H., Mickiene, D., Petraitis, V., Petraitiene, R., Kelaher, A., Sarafandi, A., Wuerthwein, G., Bacher, J., Walsh, T.J. J. Antimicrob. Chemother. (2005) [Pubmed]
  13. Effect of ravuconazole, a new triazole antifungal, in a rat intraabdominal abscess model. Mikamo, H., Yin, X.H., Hayasaki, Y., Satoh, M., Tamaya, T. Chemotherapy. (2001) [Pubmed]
  14. New antifungal agents. Gupta, A.K., Tomas, E. Dermatologic clinics. (2003) [Pubmed]
  15. Penetration of ravuconazole, a new triazole antifungal, into rat tissues. Mikamo, H., Yin, X.H., Hayasaki, Y., Shimamura, Y., Uesugi, K., Fukayama, N., Satoh, M., Tamaya, T. Chemotherapy. (2002) [Pubmed]
  16. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. Gupta, A.K., Leonardi, C., Stoltz, R.R., Pierce, P.F., Conetta, B. Journal of the European Academy of Dermatology and Venereology : JEADV. (2005) [Pubmed]
  17. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N., Diekema, D.J. Antimicrob. Agents Chemother. (2002) [Pubmed]
  18. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N. Antimicrob. Agents Chemother. (2002) [Pubmed]
  19. Azole cross-resistance in Aspergillus fumigatus. Mosquera, J., Denning, D.W. Antimicrob. Agents Chemother. (2002) [Pubmed]
  20. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Espinel-Ingroff, A. Antimicrob. Agents Chemother. (2001) [Pubmed]
  21. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. Fung-Tomc, J.C., White, T.C., Minassian, B., Huczko, E., Bonner, D.P. Diagn. Microbiol. Infect. Dis. (1999) [Pubmed]
  22. The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. Yan, J.H., Marino, M.R., Smith, R.A., Kanamaluru, V., O'Mara, E.M., Grasela, D.M. Journal of clinical pharmacology. (2006) [Pubmed]
  23. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Urbina, J.A., Payares, G., Sanoja, C., Lira, R., Romanha, A.J. Int. J. Antimicrob. Agents (2003) [Pubmed]
WikiGenes - Universities